Selected research
Market Structure
Global AL Amyloidosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global AL Amyloidosis Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for AL Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for AL Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for AL Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for AL Amyloidosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of AL Amyloidosis Therapeutics include Janssen Pharmaceutical, Pfizer, GlaxoSmithKline Pharmaceuticals Ltd, Bristol-Myers Squibb, Spectrum Pharmaceuticals, Inc., Prothena, Oncopeptides AB, Eidos Therapeutics, Inc. and Corino Therapeutics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global AL Amyloidosis Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of AL Amyloidosis Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents AL Amyloidosis Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the AL Amyloidosis Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
AL Amyloidosis Therapeutics Segment by Company
Janssen Pharmaceutical
Pfizer
GlaxoSmithKline Pharmaceuticals Ltd
Bristol-Myers Squibb
Spectrum Pharmaceuticals, Inc.
Prothena
Oncopeptides AB
Eidos Therapeutics, Inc.
Corino Therapeutics, Inc.
Alexion Pharmaceuticals
AL Amyloidosis Therapeutics Segment by Type
Chemotherapy
Supportive Care
Surgery
Stem Cell Transplant
Targeted Therapy
AL Amyloidosis Therapeutics Segment by Application
Clinics
Hospitals
Ambulatory Service Centres
Others
AL Amyloidosis Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AL Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AL Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AL Amyloidosis Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of AL Amyloidosis Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AL Amyloidosis Therapeutics industry.
Chapter 3: Detailed analysis of AL Amyloidosis Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, AL Amyloidosis Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chemotherapy
- Supportive Care
- Surgery
- Stem Cell Transplant
- Targeted Therapy
Applications
- Clinics
- Hospitals
- Ambulatory Service Centres
- Others
Companies covered
- Janssen Pharmaceutical
- Pfizer
- GlaxoSmithKline Pharmaceuticals Ltd
- Bristol-Myers Squibb
- Spectrum Pharmaceuticals, Inc.
- Prothena
- Oncopeptides AB
- Eidos Therapeutics, Inc.
- Corino Therapeutics, Inc.
- Alexion Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global AL Amyloidosis Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Chemotherapy
- 1.2.3 Supportive Care
- 1.2.4 Surgery
- 1.2.5 Stem Cell Transplant
- 1.2.6 Targeted Therapy
- 1.3 Market Analysis by Application
- 1.3.1 Global AL Amyloidosis Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Clinics
- 1.3.3 Hospitals
- 1.3.4 Ambulatory Service Centres
- 1.3.5 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global AL Amyloidosis Therapeutics Growth Trends by Region
- 1.5.1 Global AL Amyloidosis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 AL Amyloidosis Therapeutics Market Size by Region (2021-2026)
- 1.5.3 AL Amyloidosis Therapeutics Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global AL Amyloidosis Therapeutics Market Dynamics
- 2.1 AL Amyloidosis Therapeutics Industry Trends
- 2.2 AL Amyloidosis Therapeutics Industry Drivers
- 2.3 AL Amyloidosis Therapeutics Industry Opportunities and Challenges
- 2.4 AL Amyloidosis Therapeutics Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global AL Amyloidosis Therapeutics Revenue by Company (2021-2026)
- 3.2 Global AL Amyloidosis Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global AL Amyloidosis Therapeutics Key Company Head office and Area Served
- 3.4 Global AL Amyloidosis Therapeutics Company, Product Type & Application
- 3.5 Global AL Amyloidosis Therapeutics Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global AL Amyloidosis Therapeutics Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 AL Amyloidosis Therapeutics Players Market Share by Revenue in 2025
- 3.6.3 2025 AL Amyloidosis Therapeutics Tier 1, Tier 2, and Tier 3
4 AL Amyloidosis Therapeutics Market by Type
- 4.1 Global AL Amyloidosis Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global AL Amyloidosis Therapeutics Market Size by Type (2021-2032)
- 4.3 Global AL Amyloidosis Therapeutics Market Size Share by Type (2021-2032)
5 AL Amyloidosis Therapeutics Market by Application
- 5.1 Global AL Amyloidosis Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global AL Amyloidosis Therapeutics Market Size by Application (2021-2032)
- 5.3 Global AL Amyloidosis Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Janssen Pharmaceutical
- 6.1.1 Janssen Pharmaceutical Company Information
- 6.1.2 Janssen Pharmaceutical Business Overview
- 6.1.3 Janssen Pharmaceutical AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Janssen Pharmaceutical AL Amyloidosis Therapeutics Product Portfolio
- 6.1.5 Janssen Pharmaceutical Recent Developments
- 6.2 Pfizer
- 6.2.1 Pfizer Company Information
- 6.2.2 Pfizer Business Overview
- 6.2.3 Pfizer AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Pfizer AL Amyloidosis Therapeutics Product Portfolio
- 6.2.5 Pfizer Recent Developments
- 6.3 GlaxoSmithKline Pharmaceuticals Ltd
- 6.3.1 GlaxoSmithKline Pharmaceuticals Ltd Company Information
- 6.3.2 GlaxoSmithKline Pharmaceuticals Ltd Business Overview
- 6.3.3 GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 GlaxoSmithKline Pharmaceuticals Ltd AL Amyloidosis Therapeutics Product Portfolio
- 6.3.5 GlaxoSmithKline Pharmaceuticals Ltd Recent Developments
- 6.4 Bristol-Myers Squibb
- 6.4.1 Bristol-Myers Squibb Company Information
- 6.4.2 Bristol-Myers Squibb Business Overview
- 6.4.3 Bristol-Myers Squibb AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Bristol-Myers Squibb AL Amyloidosis Therapeutics Product Portfolio
- 6.4.5 Bristol-Myers Squibb Recent Developments
- 6.5 Spectrum Pharmaceuticals, Inc.
- 6.5.1 Spectrum Pharmaceuticals, Inc. Company Information
- 6.5.2 Spectrum Pharmaceuticals, Inc. Business Overview
- 6.5.3 Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Spectrum Pharmaceuticals, Inc. AL Amyloidosis Therapeutics Product Portfolio
- 6.5.5 Spectrum Pharmaceuticals, Inc. Recent Developments
- 6.6 Prothena
- 6.6.1 Prothena Company Information
- 6.6.2 Prothena Business Overview
- 6.6.3 Prothena AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Prothena AL Amyloidosis Therapeutics Product Portfolio
- 6.6.5 Prothena Recent Developments
- 6.7 Oncopeptides AB
- 6.7.1 Oncopeptides AB Company Information
- 6.7.2 Oncopeptides AB Business Overview
- 6.7.3 Oncopeptides AB AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Oncopeptides AB AL Amyloidosis Therapeutics Product Portfolio
- 6.7.5 Oncopeptides AB Recent Developments
- 6.8 Eidos Therapeutics, Inc.
- 6.8.1 Eidos Therapeutics, Inc. Company Information
- 6.8.2 Eidos Therapeutics, Inc. Business Overview
- 6.8.3 Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Eidos Therapeutics, Inc. AL Amyloidosis Therapeutics Product Portfolio
- 6.8.5 Eidos Therapeutics, Inc. Recent Developments
- 6.9 Corino Therapeutics, Inc.
- 6.9.1 Corino Therapeutics, Inc. Company Information
- 6.9.2 Corino Therapeutics, Inc. Business Overview
- 6.9.3 Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Corino Therapeutics, Inc. AL Amyloidosis Therapeutics Product Portfolio
- 6.9.5 Corino Therapeutics, Inc. Recent Developments
- 6.10 Alexion Pharmaceuticals
- 6.10.1 Alexion Pharmaceuticals Company Information
- 6.10.2 Alexion Pharmaceuticals Business Overview
- 6.10.3 Alexion Pharmaceuticals AL Amyloidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Alexion Pharmaceuticals AL Amyloidosis Therapeutics Product Portfolio
- 6.10.5 Alexion Pharmaceuticals Recent Developments
7 North America
- 7.1 North America AL Amyloidosis Therapeutics Market Size (2021-2032)
- 7.2 North America AL Amyloidosis Therapeutics Market Size by Type
- 7.2.1 North America AL Amyloidosis Therapeutics Market Size by Type (2021-2026)
- 7.2.2 North America AL Amyloidosis Therapeutics Market Size by Type (2027-2032)
- 7.2.3 North America AL Amyloidosis Therapeutics Market Share by Type (2021-2032)
- 7.3 North America AL Amyloidosis Therapeutics Market Size by Application
- 7.3.1 North America AL Amyloidosis Therapeutics Market Size by Application (2021-2026)
- 7.3.2 North America AL Amyloidosis Therapeutics Market Size by Application (2027-2032)
- 7.3.3 North America AL Amyloidosis Therapeutics Market Share by Application (2021-2032)
- 7.4 North America AL Amyloidosis Therapeutics Market Size by Country
- 7.4.1 North America AL Amyloidosis Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 7.4.3 North America AL Amyloidosis Therapeutics Market Size by Country (2027-2032)
- 7.4.4 North America AL Amyloidosis Therapeutics Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe AL Amyloidosis Therapeutics Market Size (2021-2032)
- 8.2 Europe AL Amyloidosis Therapeutics Market Size by Type
- 8.2.1 Europe AL Amyloidosis Therapeutics Market Size by Type (2021-2026)
- 8.2.2 Europe AL Amyloidosis Therapeutics Market Size by Type (2027-2032)
- 8.2.3 Europe AL Amyloidosis Therapeutics Market Share by Type (2021-2032)
- 8.3 Europe AL Amyloidosis Therapeutics Market Size by Application
- 8.3.1 Europe AL Amyloidosis Therapeutics Market Size by Application (2021-2026)
- 8.3.2 Europe AL Amyloidosis Therapeutics Market Size by Application (2027-2032)
- 8.3.3 Europe AL Amyloidosis Therapeutics Market Share by Application (2021-2032)
- 8.4 Europe AL Amyloidosis Therapeutics Market Size by Country
- 8.4.1 Europe AL Amyloidosis Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 8.4.3 Europe AL Amyloidosis Therapeutics Market Size by Country (2027-2032)
- 8.4.4 Europe AL Amyloidosis Therapeutics Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China AL Amyloidosis Therapeutics Market Size (2021-2032)
- 9.2 China AL Amyloidosis Therapeutics Market Size by Type
- 9.2.1 China AL Amyloidosis Therapeutics Market Size by Type (2021-2026)
- 9.2.2 China AL Amyloidosis Therapeutics Market Size by Type (2027-2032)
- 9.2.3 China AL Amyloidosis Therapeutics Market Share by Type (2021-2032)
- 9.3 China AL Amyloidosis Therapeutics Market Size by Application
- 9.3.1 China AL Amyloidosis Therapeutics Market Size by Application (2021-2026)
- 9.3.2 China AL Amyloidosis Therapeutics Market Size by Application (2027-2032)
- 9.3.3 China AL Amyloidosis Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia AL Amyloidosis Therapeutics Market Size (2021-2032)
- 10.2 Asia AL Amyloidosis Therapeutics Market Size by Type
- 10.2.1 Asia AL Amyloidosis Therapeutics Market Size by Type (2021-2026)
- 10.2.2 Asia AL Amyloidosis Therapeutics Market Size by Type (2027-2032)
- 10.2.3 Asia AL Amyloidosis Therapeutics Market Share by Type (2021-2032)
- 10.3 Asia AL Amyloidosis Therapeutics Market Size by Application
- 10.3.1 Asia AL Amyloidosis Therapeutics Market Size by Application (2021-2026)
- 10.3.2 Asia AL Amyloidosis Therapeutics Market Size by Application (2027-2032)
- 10.3.3 Asia AL Amyloidosis Therapeutics Market Share by Application (2021-2032)
- 10.4 Asia AL Amyloidosis Therapeutics Market Size by Country
- 10.4.1 Asia AL Amyloidosis Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 10.4.3 Asia AL Amyloidosis Therapeutics Market Size by Country (2027-2032)
- 10.4.4 Asia AL Amyloidosis Therapeutics Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size (2021-2032)
- 11.2 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size by Type
- 11.2.1 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size by Application
- 11.3.1 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size by Country
- 11.4.1 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa AL Amyloidosis Therapeutics Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst